March 28, 2007 – Sanofi-Aventis will spend up to $680 million to partner with Oxford BioMedica on its cancer vaccine, TroVax; Arena sold its headquarters buildings in San Diego for $50 million in a sale-leaseback transaction; Merck and Lundbeck A/S will stop development of the new sedative drug, gaboxadol; Pfizer put a new glaucoma drug into a Phase I trial; Penwest will collaborate with Pharmaceutics International to develop drugs for new delivery methods; Pharmacopeia will receive a $1 million milestone from Schering-Plough for starting trials of a drug for inflammatory diseases; EndoCeutics set the terms for its upcoming IPO; Genetech will invest $140 million to build a plant in Singapore; and United Therapeutics out-licensed the Japanese rights for Remodulin. The Centient Biotech 200™ closed with a loss of 17 points at 3850, a .45% drop. More details...
